FDA Publishes Q&A on GMPs for APIs
The new document answers questions regarding implementation of the ICH Q7 guidance on GMPs for APIs.
On April 19, 2018, FDA published a guidance document that answers questions about the implementation of the International Council for Harmonization (ICH) Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients. ICH Q7 helps pharmaceutical companies ensure that APIs meet quality and purity characteristics. This Q&A document is in response to industry requests for clarification of some ICH Q7 sections.
Topics addressed in the Q&A document include quality management, personnel training, facilities, process equipment, documentation, materials management, production, storage, and validation. Specifically, the document clarifies requirements for releasing raw materials, sampling, product quality review, risk management, acceptance criteria, evaluation of material suppliers, and more.
Source: FDA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
